GlucoTrack (GCTK) elects Victoria Carr-Brendel to Board

Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today that Victoria E. Carr-Brendel, PhD, was elected to the Company’s Board of Directors, effective May 22, 2025.

“We are delighted to welcome Dr. Carr-Brendel to Glucotrack’s Board of Directors,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “With her exceptional leadership in medical devices and deep expertise in implantable technologies, she will be an invaluable addition to the Board as we advance our continuous blood glucose monitoring (CBGM) technology through clinical development and move closer to commercialization.”

Dr. Carr-Brendel currently serves as a member of the board of directors of Vicarious Surgical Inc. (NYSE: RBOT) since January 2023 and previously served from 2018 to 2024 as President and Group Vice President of Cochlear Implants at Sonova Group. Prior to that, she served as Chief Executive Officer of JenaValve Technology, Inc., a medical device company focused on developing minimally invasive transcatheter aortic valve repair systems for patients suffering from severe aortic valve disease. Previously, Dr. Carr-Brendel held various leadership roles at Boston Scientific, including overseeing the acquisition of Bayer’s interventional radiology division in 2014. She started her career as a scientist in R&D with roles at Dexcom and Baxter Healthcare, amassing over forty patents and taking on increasingly senior business and management roles. She holds a BA in Biology from Monmouth College, an MS in Microbiology from Iowa State University, and a PhD in Microbiology and Immunology from the University of Illinois at Chicago.

“I am honored to be joining Glucotrack’s Board of Directors at this pivotal time in the company’s development,” said Victoria E. Carr-Brendel, PhD. “The innovative CBGM has tremendous potential to address significant unmet needs for people with diabetes and enhance automated insulin delivery. I look forward to contributing to the Company as it works to achieve its strategic and clinical milestones.”

Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous, accurate blood glucose monitoring, offering a more convenient and less intrusive glucose monitoring solution. The CBGM measures glucose directly from blood, unlike traditional continuous glucose monitoring systems which measure glucose from interstitial fluid. Thus, it aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.

The Glucotrack Continuous Blood Glucose Monitor is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information about Glucotrack’s CBGM technology, visit glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

You May Also Be Interested In

• Correction: Kepler Cheuvreux Upgrades Siemens AG (SIE:GR) (SIEGY) to Hold
• Alarum Technologies responds to FBI investigation of subsidiary NetNut
• Aon plc (AON) files mixed shelf